









Märkte
/
Aktien
/
nasdaq-abbv
/

AbbVie Inc

ABBV

191.080USD

-1.339-0.70%

Handelsschluss 06/13, 16:00（ET）Kurse um 15 Minuten verzögert

337.50BMarktkapitalisierung

79.64KGV TTM



AbbVie Inc

191.080

-1.339-0.70%

Unternehmen

mehr Informationen über AbbVie Inc Unternehmen

AbbVie Inc. is a global, diversified research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.

Unternehmensinformationen

BörsenkürzelABBV

Name des UnternehmensAbbVie Inc

IPO-datumJan 02, 2013

Gegründet am2012

CEOMr. Robert A. Michael, CPA

Anzahl der mitarbeiter55000

WertpapierartOrdinary Share

GeschäftsjahresendeJan 02

Addresse1 N Waukegan Rd

StadtNORTH CHICAGO

BörseNYSE Consolidated

LandUnited States of America

Postleitzahl60064

Telefon18479327900

Websitehttps://www.abbvie.com/

BörsenkürzelABBV

IPO-datumJan 02, 2013

Gegründet am2012

Führungskräfte

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Richard A. Gonzalez

Executive Chairman of the Board

386.48K

-2.18%

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

183.77K

-17.22%

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

134.63K

+0.90%

Mr. Glenn Fletcher Tilton

Independent Director

51.91K

+2.37%

Mr. Edward J. (Ed) Rapp

Independent Director

42.95K

+2.88%

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

42.28K

+16.15%

Ms. Roxanne S. Austin, CPA

Lead Independent Director

38.46K

+3.23%

Dr. Robert J. Alpern, M.D.

Independent Director

35.65K

+3.49%

Mr. Frederick H. (Rick) Waddell

Independent Director

28.96K

+4.33%

Ms. Melody B. Meyer

Independent Director

16.50K

+7.87%

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Richard A. Gonzalez

Executive Chairman of the Board

386.48K

-2.18%

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

183.77K

-17.22%

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

134.63K

+0.90%

Mr. Glenn Fletcher Tilton

Independent Director

51.91K

+2.37%

Mr. Edward J. (Ed) Rapp

Independent Director

42.95K

+2.88%

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

42.28K

+16.15%

Umsatzaufteilung

Währung: USDAktualisiert: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Immunology-SKYRIZI

11.72B

20.80%

Immunology-HUMIRA

8.99B

15.96%

Immunology-RINVOQ

5.97B

10.60%

Hematologic Oncology-IMBRUVICA

3.35B

5.94%

Neuroscience-Botox Therapeutic

3.28B

5.83%

Other

23.02B

40.87%

Nach RegionUSD

Name

Umsatz

Anteil

United States

40.78B

72.39%

International

11.51B

20.42%

All other countries

3.03B

5.38%

Germany

1.47B

2.60%

Japan

1.12B

1.99%

Other

-1.57B

-2.79%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Immunology-SKYRIZI

11.72B

20.80%

Immunology-HUMIRA

8.99B

15.96%

Immunology-RINVOQ

5.97B

10.60%

Hematologic Oncology-IMBRUVICA

3.35B

5.94%

Neuroscience-Botox Therapeutic

3.28B

5.83%

Other

23.02B

40.87%

Aktionärsstatistik

Aktualisiert: Fri, Feb 21

Aktionäre

Aktionärstypen

Aktionäre

Anteil

The Vanguard Group, Inc.

9.80%

BlackRock Institutional Trust Company, N.A.

5.15%

State Street Global Advisors (US)

4.53%

Geode Capital Management, L.L.C.

2.17%

JP Morgan Asset Management

2.02%

Other

76.34%

Aktionäre

Anteil

The Vanguard Group, Inc.

9.80%

BlackRock Institutional Trust Company, N.A.

5.15%

State Street Global Advisors (US)

4.53%

Geode Capital Management, L.L.C.

2.17%

JP Morgan Asset Management

2.02%

Other

76.34%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

34.13%

Investment Advisor/Hedge Fund

29.68%

Research Firm

3.16%

Bank and Trust

2.22%

Pension Fund

2.19%

Sovereign Wealth Fund

1.54%

Hedge Fund

0.70%

Insurance Company

0.67%

Family Office

0.20%

Other

25.51%

Institutionelle Beteiligung

Aktualisiert: Thu, Feb 20

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q1

5261

1.32B

74.47%

+9.10M

2024Q4

5219

1.31B

74.47%

+8.91M

2024Q3

4974

1.30B

73.54%

-7.44M

2024Q2

4916

1.30B

73.53%

+2.27M

2024Q1

4930

1.29B

72.58%

-1.47M

2023Q4

4882

1.28B

72.31%

-1.48M

2023Q3

4694

1.27B

71.87%

-12.06M

2023Q2

4688

1.26B

71.51%

-30.42M

2023Q1

4658

1.27B

71.97%

-18.58M

2022Q4

4628

1.27B

71.69%

-10.55M

Aktionärsaktivitäten

Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

The Vanguard Group, Inc.

172.31M

9.74%

+1.45M

+0.85%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

90.08M

5.09%

+893.98K

+1.00%

Dec 31, 2024

State Street Global Advisors (US)

79.62M

4.5%

+553.55K

+0.70%

Dec 31, 2024

Geode Capital Management, L.L.C.

37.14M

2.1%

+983.89K

+2.72%

Dec 31, 2024

JP Morgan Asset Management

33.90M

1.92%

+881.83K

+2.67%

Dec 31, 2024

Capital Research Global Investors

33.98M

1.92%

+778.13K

+2.34%

Dec 31, 2024

Charles Schwab Investment Management, Inc.

27.44M

1.55%

+3.60M

+15.10%

Dec 31, 2024

Norges Bank Investment Management (NBIM)

25.10M

1.42%

+2.62M

+11.64%

Dec 31, 2024

Morgan Stanley Smith Barney LLC

22.68M

1.28%

+844.34K

+3.87%

Dec 31, 2024

Fidelity Management & Research Company LLC

16.99M

0.96%

+3.92M

+30.04%

Dec 31, 2024

Verbundene ETFs

Aktualisiert: Fri, Jun 6

Name

Anteil

First Trust Morningstar Dividend Leaders Index Fund

7.48%

First Trust NASDAQ Pharmaceuticals ETF

7.4%

Health Care Select Sector SPDR Fund

6.43%

Proshares Ultra Health Care

6.2%

iShares U.S. Healthcare ETF

6.17%

Goldman Sachs Future Health Care Equity ETF

6.1%

JPMorgan Healthcare Leaders ETF

5.85%

Fidelity MSCI Health Care Index ETF

5.55%

Direxion Daily Healthcare Bull 3X Shares

5.19%

VanEck Pharmaceutical ETF

5.06%

First Trust Morningstar Dividend Leaders Index Fund

Anteil7.48%

First Trust NASDAQ Pharmaceuticals ETF

Anteil7.4%

Health Care Select Sector SPDR Fund

Anteil6.43%

Proshares Ultra Health Care

Anteil6.2%

iShares U.S. Healthcare ETF

Anteil6.17%

Goldman Sachs Future Health Care Equity ETF

Anteil6.1%

JPMorgan Healthcare Leaders ETF

Anteil5.85%

Fidelity MSCI Health Care Index ETF

Anteil5.55%

Direxion Daily Healthcare Bull 3X Shares

Anteil5.19%

VanEck Pharmaceutical ETF

Anteil5.06%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 48.58B USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Oct 30, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025

Jan 15, 2025

Feb 14, 2025

Jan 15, 2025

Sep 06, 2024

ABBV.NB Final Cash Dividend of gross USD 1.55 paid on Nov 15, 2024 going ex on Oct 15, 2024 with reinvestment option

Oct 15, 2024

Nov 15, 2024

Oct 15, 2024

Jun 21, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option

Jul 15, 2024

Aug 15, 2024

Jul 15, 2024

Feb 15, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on May 15, 2024 going ex on Apr 12, 2024 with reinvestment option

Apr 15, 2024

May 15, 2024

Apr 12, 2024

Oct 27, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Feb 15, 2024 going ex on Jan 12, 2024 with reinvestment option

Jan 16, 2024

Feb 15, 2024

Jan 12, 2024

Sep 11, 2023

ABBV.NB Final Cash Dividend of gross USD 1.48 paid on Nov 15, 2023 going ex on Oct 12, 2023 with reinvestment option

Oct 13, 2023

Nov 15, 2023

Oct 12, 2023

Jun 22, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Aug 15, 2023 going ex on Jul 13, 2023 with reinvestment option

Jul 14, 2023

Aug 15, 2023

Jul 13, 2023

Feb 16, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on May 15, 2023 going ex on Apr 13, 2023 with reinvestment option

Apr 14, 2023

May 15, 2023

Apr 13, 2023

Oct 28, 2022

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Feb 15, 2023 going ex on Jan 12, 2023 with reinvestment option

Jan 13, 2023

Feb 15, 2023

Jan 12, 2023

Sep 09, 2022

ABBV.NB Final Cash Dividend of gross USD 1.41 paid on Nov 15, 2022 going ex on Oct 13, 2022 with reinvestment option

Oct 14, 2022

Nov 15, 2022

Oct 13, 2022

Aktien-Split

Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten

KeyAI



AbbVie Inc

191.080USD

AbbVie Inc

191.080

Übersicht

Unternehmen